Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
27 June, 2019 10:07 IST
Sun Pharma announces USFDA approval of YONSA
Source: IRIS | 23 May, 2018, 09.51AM
Comments  |  Post Comment

Sun Pharmaceutical Industries and Churchill Pharmaceuticals, LLC. (Churchill) announced that one of Sun Pharma’s wholly owned subsidiary companies has received approval from the U.S. Food and Drug Administration (FDA) for YONSA (abiraterone acetate), a novel formulation in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Churchill is eligible to receive upfront and sales-linked milestone payments, and royalties on sales from Sun Pharma (Q,N,C,F)* pursuant to an agreement between the two companies to commercialize YONSA in the U.S.

''We are pleased to add YONSA to our growing oncology portfolio and continue to deliver on Sun Pharma's commitment for enhanced patient access to innovative cancer therapies,'' said Abhay Gandhi, CEO-North America, Sun Pharma.

YONSA in combination with methylprednisolone was filed as a New Drug Application (NDA) under the 505(b)(2) regulatory pathway and will be promoted as a branded product in the U.S.

Shares of the company gained Rs 5.15, or 1.14%, to trade at Rs 458.15. The total volume of shares traded was 54,333 at the BSE (9.36 a.m., Wednesday).



Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer